Carvedilol in comparison and in combination with isosorbide dinitrate sustained release in patients with chronic stable effort-induced angina pectoris

Clinical Drug Investigation

Volumn 14, Issue 6, 1997, Pages 465-473

  Hauf Zachariou, U ^a,c   Pfarr, E ^a   Van Der Does, R ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b IST Studien Therapeutica GmbH   (Germany)

^c Department of Clinical Research ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE TEST; FEMALE; HEADACHE; HEART RATE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT DEPRESSION; SUSTAINED RELEASE PREPARATION; URINARY TRACT INFECTION; VERTIGO;

EID: 0031468224     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714060-00004     Document Type: Article

References (29)

1. Feuerstein GZ, Poste G, Ruffolo R. Carvedilol update III: rationale for use in congestive heart failure. Drugs Today 1995; 31 Suppl. F: 1-23
2. Nichols AJ, Sulpizio AC, Ashton DJ, et al. In vitro pharmacologic profile of the novel β-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989; 39: 327-36
3. Nichols AJ, Sulpizio AC, Ashton DJ, et al. The interaction of the enantiomers of carvedilol with α1-β1-adrenoceptors. Chirality 1989; 1 (4): 265-70
4. Sponer G, Bartsch W, Strein K, et al. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987; 9: 317-27
5. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90 (13): 6189-93
6. Ohlstein EH, Vickery L, Arleth A, et al. Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 1994; 16 (2): 163-77
7. Douglas SA, Vickery-Clark LM, Louden C, et al. Acute protreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Commun 1994; 5 (1): 65-72
8. Hamburger SA, Barone FC, Feuerstein GZ, et al. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991; 43 (3): 113-20
9. Bril A, Slivjak M, Di Martino MJ, et al. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992; 26 (5): 518-25
10. Feuerstein GZ, Hamburger SA, Smith EF, et al. Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: 138-41
11. Feuerstein GZ, Ruffolo RR. Comparison of the ability of two vasodilating β-blockers, carvedilol and celiprolol, to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol Commun 1994; 5 (1): 57-63
12. Lopez BL, Christopher TA, Yue T-L, et al. Carvedilol, a new β-adrenoceptor blocker and free radical scavenger, attenuates myocardial ischaemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1995; 273 (1): 64-71
13. Yue T-L, Wang X, Gu J-L, et al. Carvedilol, a new vasodilating β-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leucocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995; 273 (3): 1442-9
14. Bril A, Tomasi V, Laville MP. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun 1995; 5: 291-300
15. Kaski JC, Rodriguez-Plaza L, Brown J, et al. Efficacy of carvedilol in exercise-induced myocardial ischemia. Am J Cardiol 1985; 10 Suppl. 11: 137-40
16. Rodrigues EA, Lahiri A, Hughes LO, et al. Anti-anginal efficacy of carvedilol, a new beta-blocking drug with vasodilating activity. Am J Cardiol 1986; 58: 916-21
17. van der Does R, Eberhardt R, Derr I, et al. Treatment of chronic stable angina with carvedilol in comparison with nifedipine SR. Eur Heart J 1991; 12: 60-4
18. Nahrendorf W, Rading A, Steinig G, et al. A comparison of carvedilol with a combination of propranolol/isosorbide-dinitrate in the chronic treatment of stable angina. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: 114-6
19. Lahiri A, Rodrigues EA, Al-Khawaja I, et al. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. Am J Cardiol 1987; 59: 769-74
20. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995; 25: 1225-31
21. Packer M, Bristcw MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55
22. Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo controlled, randomised trial. Circulation 1997; 96 (1): 183-91
23. Bristol JR, Castellana JV. Survival analysis techniques in angina pectoris trials. Stat Med 1990; 9: 293-9
24. Thadani U, Fung H-L, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982; 49: 411
25. Jansen W, Osterspey A, Tauchert M, et al. 5-Isosorbid-mononitral unter Ruhe- und Belastungsbedingungen bei Jansen W, Osterspey A, Tauchert M, Schmid G, Schell U, Fuchs M, Hombach V, Hilger HH. 5-Isosorbidmononitrat unter Ruhe- und Belastungsbedingungen bei koronarer Herzkrankheit. Dtsch Med Wochenschr 1982; 107: 1499
26. Silber S, Krause KH, Garner C, et al. Anti-ischaemic effects of an 80mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80mg once daily or twice daily. Z Kardiol 1983; 72 Suppl. 3: 211
27. Rennhak Z, Riebesel T, Biamino G. A double-blind cross-over study on the effectiveness and possible development of tolerance during long term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow-release in coronary artery disease. In: Cohn JN, Rittinghausen R, editors. Mononitrates. Berlin: Springer Verlag, 1984: 147-53
28. Silber S. Clinical relevance of nitrate tolerance. In: Cohn JN, Rittinghausen R, editors. Mononitrates. Berlin: Springer Verlag, 1984: 130-46
29. Rudolph W, Blasini R, Froer K-L, et al. Effects of acute and chronic administration of isosorbide dinitrate, sustained-release form, in patients with angina pectoris. In: Lichtlen PR, Engel H-J, Schrey A, Swan HJC, editors. Nitrates III. Cardiovascular effects. Berlin: Springer Verlag, 1981: 75-81